SBIR-STTR Award

Novel Nano-emulsion Immuno-suppressive Adjuvant for Allergy Vaccines
Award last edited on: 8/18/20

Sponsored Program
SBIR
Awarding Agency
NIH
Total Award Amount
$600,000
Award Phase
1
Solicitation Topic Code
NIAID
Principal Investigator
Michael S Vajdy

Company Information

EpitoGenesis Inc

933 Hartford Turnpike
Vernon, CT 06066
   (860) 990-5908
   info@epitogenesis.com
   www.epitogenesis.com
Location: Single
Congr. District: 02
County: Tolland

Phase I

Contract Number: 75N93019C00039
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2019
Phase I Amount
$600,000
Bronchial asthma is a chronic respiratory disease that can be lethal Asthma is a global health problem According to the CDC in USA there are currently million asthma sufferers and this number is increasing Half of the asthma patients have at least one hospitalization per year with an annual medical cost of $B Traditionally asthma is treated during flare ups with prescribed inhaled corticosteriods In recent years various forms of immunotherapies such as sublingual treatment with large doses of allergens have been used to alleviate symptomsIn modern vaccine adjuvant research the concept of allergen specific therapeutic allergy vaccines are introduced We previously developed an immune enhancing vaccine adjuvant formulation based on the synergy between vitamins A and E and a flavonoid as an oil in water emulsion NIDS and obtained safety and protective efficacy as well as long term shelf stability results for rather result in antigen specific suppression of serum antibody responses following intra muscular vaccinations This together with the fact that the components used can be anti inflammatory lead us to design a therapeutic allergy vaccine adjuvant platform as proposed herein

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----